NGF and neoplasm: In preclinical models of cervical and breast cancer, anti-NGF antibodies and the Trk tyrosine kinase inhibitor GNF-5837 have demonstrated promising anti-tumor efficacy [130, 160], though further clinical validation is needed to establish therapeutic relevance.